Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Ireland-based inflammatory disease drug developer Inflazome was acquired by pharmaceutical firm Roche today for €380m ($448m) in an upfront payment, providing an exit to pharmaceutical firm Novartis.
Inflazome is eligible to receive additional milestone payments, but details were not revealed.
Founded in 2016, Inflazome is working on drugs that target inflammasomes, which drive chronic inflammatory conditions ranging from Parkinson’s and Alzheimer’s diseases to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease and arthritis.
The company is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in